First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors
ObjectiveThis study attempted to comprehensively assess the clinical outcomes of cases with progressive HCC (pHCC) undergoing treatment with TKI and ICI in conjunction with TACE, as compared to the combination of TKI with TACE alone.MethodsFrom March 2019 to January 2022, this cohort comprised 82 ca...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1533471/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850034777651937280 |
|---|---|
| author | Yanjun Shen Yawen Xu Ying Teng Xiaoyan Ding Jinglong Chen |
| author_facet | Yanjun Shen Yawen Xu Ying Teng Xiaoyan Ding Jinglong Chen |
| author_sort | Yanjun Shen |
| collection | DOAJ |
| description | ObjectiveThis study attempted to comprehensively assess the clinical outcomes of cases with progressive HCC (pHCC) undergoing treatment with TKI and ICI in conjunction with TACE, as compared to the combination of TKI with TACE alone.MethodsFrom March 2019 to January 2022, this cohort comprised 82 cases who received TACE in conjunction with TKI and 52 cases who were treated with TACE plus TKI alone. The propensity scores was used to mitigate selection bias.ResultsThe multivariate analysis further reinforced that liver cirrhosis (HR = 1.233, 95% CI: 1.024–1.484, P = 0.027), tumor diameter (HR = 1.283, 95% CI: 1.086–1.515, P = 0.003), and the treatment strategy (HR = 0.495, 95% CI: 0.264–0.793, P = 0.000) were independently linked to OS, underscoring their prognostic relevance.ConclusionIncorporating TACE, TKI, and ICI remarkably enhanced both PFS and OS relative to TACE with TKI alone, positioning it as a more efficacious first-line therapeutic strategy for unresectable HCC, while maintaining an acceptable safety profile in clinical settings. |
| format | Article |
| id | doaj-art-acca9e285ab04da7ad4456f8a309321c |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-acca9e285ab04da7ad4456f8a309321c2025-08-20T02:57:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15334711533471First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitorsYanjun ShenYawen XuYing TengXiaoyan DingJinglong ChenObjectiveThis study attempted to comprehensively assess the clinical outcomes of cases with progressive HCC (pHCC) undergoing treatment with TKI and ICI in conjunction with TACE, as compared to the combination of TKI with TACE alone.MethodsFrom March 2019 to January 2022, this cohort comprised 82 cases who received TACE in conjunction with TKI and 52 cases who were treated with TACE plus TKI alone. The propensity scores was used to mitigate selection bias.ResultsThe multivariate analysis further reinforced that liver cirrhosis (HR = 1.233, 95% CI: 1.024–1.484, P = 0.027), tumor diameter (HR = 1.283, 95% CI: 1.086–1.515, P = 0.003), and the treatment strategy (HR = 0.495, 95% CI: 0.264–0.793, P = 0.000) were independently linked to OS, underscoring their prognostic relevance.ConclusionIncorporating TACE, TKI, and ICI remarkably enhanced both PFS and OS relative to TACE with TKI alone, positioning it as a more efficacious first-line therapeutic strategy for unresectable HCC, while maintaining an acceptable safety profile in clinical settings.https://www.frontiersin.org/articles/10.3389/fphar.2025.1533471/fullhepatocellular carcinomatransarterial chemoembolizationtyrosine kinase inhibitorimmune checkpoint inhibitorpropensity scores |
| spellingShingle | Yanjun Shen Yawen Xu Ying Teng Xiaoyan Ding Jinglong Chen First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors Frontiers in Pharmacology hepatocellular carcinoma transarterial chemoembolization tyrosine kinase inhibitor immune checkpoint inhibitor propensity scores |
| title | First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors |
| title_full | First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors |
| title_fullStr | First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors |
| title_full_unstemmed | First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors |
| title_short | First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors |
| title_sort | first line treatment of hepatocellular carcinoma a propensity matched analysis of tyrosine kinase inhibitors combined with tace with or without pd 1 inhibitors |
| topic | hepatocellular carcinoma transarterial chemoembolization tyrosine kinase inhibitor immune checkpoint inhibitor propensity scores |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1533471/full |
| work_keys_str_mv | AT yanjunshen firstlinetreatmentofhepatocellularcarcinomaapropensitymatchedanalysisoftyrosinekinaseinhibitorscombinedwithtacewithorwithoutpd1inhibitors AT yawenxu firstlinetreatmentofhepatocellularcarcinomaapropensitymatchedanalysisoftyrosinekinaseinhibitorscombinedwithtacewithorwithoutpd1inhibitors AT yingteng firstlinetreatmentofhepatocellularcarcinomaapropensitymatchedanalysisoftyrosinekinaseinhibitorscombinedwithtacewithorwithoutpd1inhibitors AT xiaoyanding firstlinetreatmentofhepatocellularcarcinomaapropensitymatchedanalysisoftyrosinekinaseinhibitorscombinedwithtacewithorwithoutpd1inhibitors AT jinglongchen firstlinetreatmentofhepatocellularcarcinomaapropensitymatchedanalysisoftyrosinekinaseinhibitorscombinedwithtacewithorwithoutpd1inhibitors |